ITUB20160180A1 - TOPICAL / LOCAL ADMINISTRATION OF ESAFOSPHATE INOSITOLO AS A ADJUVANT IN ANTITUMOR TREATMENTS - Google Patents

TOPICAL / LOCAL ADMINISTRATION OF ESAFOSPHATE INOSITOLO AS A ADJUVANT IN ANTITUMOR TREATMENTS

Info

Publication number
ITUB20160180A1
ITUB20160180A1 ITUB2016A000180A ITUB20160180A ITUB20160180A1 IT UB20160180 A1 ITUB20160180 A1 IT UB20160180A1 IT UB2016A000180 A ITUB2016A000180 A IT UB2016A000180A IT UB20160180 A ITUB20160180 A IT UB20160180A IT UB20160180 A1 ITUB20160180 A1 IT UB20160180A1
Authority
IT
Italy
Prior art keywords
inositolo
esafosphate
adjuvant
topical
local administration
Prior art date
Application number
ITUB2016A000180A
Other languages
Italian (it)
Inventor
Vittorio Unfer
Original Assignee
Lo Li Pharma Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lo Li Pharma Srl filed Critical Lo Li Pharma Srl
Priority to ITUB2016A000180A priority Critical patent/ITUB20160180A1/en
Priority to EP17711747.0A priority patent/EP3407891A1/en
Priority to PCT/IB2017/050406 priority patent/WO2017130126A1/en
Priority to PCT/IB2017/050486 priority patent/WO2017130171A1/en
Publication of ITUB20160180A1 publication Critical patent/ITUB20160180A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q30/00—Commerce
    • G06Q30/06—Buying, selling or leasing transactions
    • G06Q30/0601—Electronic shopping [e-shopping]
    • G06Q30/0611—Request for offers or quotes
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q30/00—Commerce
    • G06Q30/06—Buying, selling or leasing transactions
    • G06Q30/0601—Electronic shopping [e-shopping]
    • G06Q30/0613—Third-party assisted
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q30/00—Commerce
    • G06Q30/06—Buying, selling or leasing transactions
    • G06Q30/08—Auctions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms

Landscapes

  • Health & Medical Sciences (AREA)
  • Business, Economics & Management (AREA)
  • Chemical & Material Sciences (AREA)
  • Accounting & Taxation (AREA)
  • Medicinal Chemistry (AREA)
  • Finance (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Development Economics (AREA)
  • General Physics & Mathematics (AREA)
  • Theoretical Computer Science (AREA)
  • Engineering & Computer Science (AREA)
  • Economics (AREA)
  • Marketing (AREA)
  • Strategic Management (AREA)
  • Physics & Mathematics (AREA)
  • General Business, Economics & Management (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Entrepreneurship & Innovation (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
ITUB2016A000180A 2016-01-27 2016-01-27 TOPICAL / LOCAL ADMINISTRATION OF ESAFOSPHATE INOSITOLO AS A ADJUVANT IN ANTITUMOR TREATMENTS ITUB20160180A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
ITUB2016A000180A ITUB20160180A1 (en) 2016-01-27 2016-01-27 TOPICAL / LOCAL ADMINISTRATION OF ESAFOSPHATE INOSITOLO AS A ADJUVANT IN ANTITUMOR TREATMENTS
EP17711747.0A EP3407891A1 (en) 2016-01-27 2017-01-26 Topical/local administration of inositol hexaphosphate as an adjuvant in anticancer treatments
PCT/IB2017/050406 WO2017130126A1 (en) 2016-01-27 2017-01-26 Topical/local administration of inositol hexaphosphate as an adjuvant in anticancer treatments
PCT/IB2017/050486 WO2017130171A1 (en) 2016-01-27 2017-01-30 System for the electronic management of business transactions

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITUB2016A000180A ITUB20160180A1 (en) 2016-01-27 2016-01-27 TOPICAL / LOCAL ADMINISTRATION OF ESAFOSPHATE INOSITOLO AS A ADJUVANT IN ANTITUMOR TREATMENTS

Publications (1)

Publication Number Publication Date
ITUB20160180A1 true ITUB20160180A1 (en) 2017-07-27

Family

ID=55806643

Family Applications (1)

Application Number Title Priority Date Filing Date
ITUB2016A000180A ITUB20160180A1 (en) 2016-01-27 2016-01-27 TOPICAL / LOCAL ADMINISTRATION OF ESAFOSPHATE INOSITOLO AS A ADJUVANT IN ANTITUMOR TREATMENTS

Country Status (3)

Country Link
EP (1) EP3407891A1 (en)
IT (1) ITUB20160180A1 (en)
WO (2) WO2017130126A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102141971B1 (en) * 2018-11-12 2020-08-06 주식회사 노암 Anticancer composition
WO2023077110A2 (en) * 2021-10-29 2023-05-04 Shamsuddin Abulkalam M Management of skin ailments

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070293458A1 (en) * 2006-06-16 2007-12-20 Ip-6 Research Inc. Prevention of nuclear, solar, and other radiation-induced tissue damage

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001063524A1 (en) * 2000-02-22 2001-08-30 General Electric Company Method and apparatus for sourcing products
US20010047311A1 (en) * 2000-04-13 2001-11-29 Bhavesh Singh Method for communicating, collaborating and transacting commerce via a communication network
US20020072987A1 (en) * 2000-06-28 2002-06-13 Chris Knudsen Methods and systems for business-to-business sourcing services
US7386475B2 (en) * 2000-10-05 2008-06-10 I2 Technologies Us, Inc. Generation and execution of custom requests for quote

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070293458A1 (en) * 2006-06-16 2007-12-20 Ip-6 Research Inc. Prevention of nuclear, solar, and other radiation-induced tissue damage

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BACIC IVAN ET AL: "Efficacy of IP6 + inositol in the treatment of breast cancer patients receiving chemotherapy: prospective, randomized, pilot clinical study", JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, BIOMED CENTRAL LTD, LONDON UK, vol. 29, no. 1, 12 February 2010 (2010-02-12), pages 12, XP021070241, ISSN: 1756-9966 *
DRUZIJANIC N ET AL: "IP6+INOSITOL AS ADJUVANT TO CHEMOTHERAPY OF COLON CANCER: OUR CLINICAL EXPERIENCE", ANTICANCER RESEARCH - INTERNATIONAL JOURNAL OF CANCER RESEARCH AND TREATMENT, INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH, GR, vol. 24, no. 5D, 1 September 2004 (2004-09-01), pages 3474 - 3475, XP009192192, ISSN: 0250-7005 *
GUPTA ET AL: "Suppression of BMBA-induced mouse skin tumor development by inositiol hehaphosphate and its mode of action", NUTRITION AND CANCER, vol. 46, no. 1, 1 December 2003 (2003-12-01), pages 66 - 72, XP009192193 *
SAKAMOTO KOSAKU: "LONG-TERM SURVIVAL OF A PATIENT WITH ADVANCED NON-SMALL CELL LUNG CANCER TREATED WITH INOSITOL HEXAPHOSPHATE (IP6) PLUS INOSITOL TREATMENT COMBINED WITH CHEMO-RADIOTHERAPY. REPORT OF CASE", ANTICANCER RESEARCH - INTERNATIONAL JOURNAL OF CANCER RESEARCH AND TREATMENT, INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH, GR, vol. 24, no. 5D, 1 September 2004 (2004-09-01), pages 3618, XP009192142, ISSN: 0250-7005, Retrieved from the Internet <URL:http://ar.iiarjournals.org/content/24/5D_Suppl/3415.full.pdf+html> *

Also Published As

Publication number Publication date
WO2017130126A1 (en) 2017-08-03
WO2017130171A1 (en) 2017-08-03
EP3407891A1 (en) 2018-12-05

Similar Documents

Publication Publication Date Title
DK3706796T3 (en) Exosomes as RNA therapeutic agents
DK3094351T3 (en) IMMUNE MODULATORY AGENTS
DK3373959T3 (en) ARENAVIRUS PARTICLES AS CANCER VACCINES
BR112016021011A2 (en) topical composition and uses of a compound
ZA201902090B (en) Combination treatments comprising administration of imidazopyrazinones
DK3532067T3 (en) LIPOSOMAL FORMULATION FOR USE IN THE TREATMENT OF CANCER
DK2994154T3 (en) ANTIMICROBIAL PEPTID
DK3089749T3 (en) COMBINED CANCER TREATMENT PREPARATIONS
HK1208378A1 (en) Pharmaceutical composition for the treatment of fungal infections
ITUA20162223A1 (en) Topical composition including plant extracts
GB201709918D0 (en) Topical formulation
DK3191085T3 (en) ABUSE-RESISTANT PHARMACEUTICAL COMPOSITIONS
DK3205661T3 (en) HSP70-DERIVED IMMUNITY-INDUCING PEPTIME
BR112017001384A2 (en) compound for use in anthelmintic treatment
BR112016021875A2 (en) topical composition
ITUB20160180A1 (en) TOPICAL / LOCAL ADMINISTRATION OF ESAFOSPHATE INOSITOLO AS A ADJUVANT IN ANTITUMOR TREATMENTS
DK3265429T3 (en) NANOPARTICLES TO USE AS ADMINISTRATION CENTERS IN SUPER conductors
EP3095453A4 (en) Topical agent for transdermal administration
DK3405197T3 (en) Topical treatment of hand eczema
DK3397619T3 (en) OINTMENT
IL246974B (en) Topical formulations of heparin
MA44394A (en) TOPICAL ANTIVIRAL COMPOSITIONS
DK3277325T3 (en) COMBINATION IMMUNE THERAPY FOR CANCER
DK3325015T3 (en) Liposomal adjuvant compositions
EP3322482C0 (en) Topical ciprofloxacin compositions